Hiring – Business Development Associate Director
Business Development Associate Director Yuhan USA Corporation Work location: Cambridge, MA Employment type: Full-time Contact Information: info@yuhan-usa.com Kindly include “[Application for BD Associate Director]” in the subject line of your email when submitting your application. Yuhan USA Corporation is seeking a driven and innovative Business Development Associate Director to join our team.This role requires proven […]
Hiring – Business Development (Senior) Manager
Business Development (Senior) Manager Yuhan USA Corporation Work location: Cambridge, MA Employment type: Full-time Contact Information: info@yuhan-usa.com Kindly include “[Application for BD (Senior) Manager]” in the subject line of your email when submitting your application. Yuhan USA Corporation is seeking a driven and innovative Business Development (Senior) Manager to join our team. This role is […]
Yuhan Secures USD 45 Million Milestone Payment for Lecraza’s Entry into the Chinese Market
Yuhan Corporation announced that it will receive a milestone payment of USD 45 million (approximately KRW 69 billion) from Janssen Biotech following the commercial launch of Lazertinib (brand name Lecraza) in China. The payment was triggered by the achievement of a development milestone related to the combination therapy of Lazertinib and Janssen’s Amivantamab (brand name […]
NEJM Publishes Phase 3 MARIPOSA Trial: Amivantamab plus Lazertinib Sets New Standard in EGFR-Mutant NSCLC
Through global collaboration with multinational pharmaceutical companies, a domestically developed anticancer drug has once again been published in the world-renowned New England Journal of Medicine (NEJM). On September 7, the final analysis of the phase 3 MARIPOSA trial in non-small cell lung cancer (NSCLC), with Professor Byoung Chul Cho of Yonsei University College of Medicine […]
Yuhan Signs HIV Drug API Supply Contract with Gilead
On the 20th, Yuhan Corporation announced that it has signed a contract with multinational pharmaceutical company Gilead Sciences to supply the active pharmaceutical ingredient (API) for HIV treatments. The contract is valued at approximately USD 60.7 million (KRW 84.27 billion), representing 4.08% of Yuhan’s total sales last year, and covers the period from March 31, […]
Lazertinib + SBRT Shows Promising Results in EGFR-Mutant Oligometastatic NSCLC
A phase 2 clinical trial led by Korean investigators demonstrated that combining the third-generation EGFR inhibitor lazertinib (Leclaza® in Korea, Lazcluzy® internationally) with stereotactic body radiotherapy (SBRT) significantly prolonged progression-free survival (PFS) compared with lazertinib alone in patients with EGFR-mutant oligometastatic non-small cell lung cancer (NSCLC). The multicenter, randomized study enrolled 67 patients with EGFR […]
Amivantamab + Lazertinib Shows Significant Benefits in EGFR-Mutant NSCLC
Johnson & Johnson’s Innovative Medicine (formerly Janssen) reported that the combination of amivantamab (Rybrevant®) and lazertinib (Leclaza® in Korea, Lazcluze® internationally), developed by Yuhan Corporation, provides a survival benefit of over one year compared with osimertinib (Tagrisso®) in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The combination also significantly reduced EGFR- and MET-related resistance, […]
Hiring – Business Development Manager
Business Development Manager Yuhan USA Corporation Work locations: Cambridge, MA Employee type: Full-time Contact Information: info@yuhan-usa.com Yuhan USA Corporation was established in January 2018 as a wholly owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 99-year heritage. As an outpost of Yuhan’s globalization strategy, Yuhan USA is searching for business development and collaboration […]
Janssen Gains China Approval for Lazertinib + Amivantamab Combo in EGFR-Mutant NSCLC
Date: 08/01/25 Yuhan Corporation’s novel EGFR-targeting non-small cell lung cancer (NSCLC) therapy Leclaza (lazertinib) has received official marketing approval in China, further solidifying its global footprint. The Chinese National Medical Products Administration (NMPA) approved the combination therapy of Leclaza and Rybrevant (amivantamab), expanding the drug’s availability to the world’s three largest pharmaceutical markets: the U.S., […]
Hiring – Part-time Operations Associate/Executive Assistant
Part-time Operations Associate/Executive AssistantYuhan USA CorporationWork locations: Cambridge, MAEmployee type: part-timeContact Information: yjlee@yuhan-usa.com Yuhan USA Corporation was established in January 2018 as a wholly owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 99-year heritage. As an outpost of Yuhan’s globalization strategy, Yuhan USA is searching for business development and collaboration opportunities in […]